Roche has moved its first artificial intelligence-driven drug discovery program forward, marking a key step in its collaboration with Recursion Pharmaceuticals. The project, which combines Roche's therapeutic expertise with Recursion's AI platform, has reached a new stage of development, the companies confirmed.
A milestone in the partnership
The advancement represents the first AI-based project to emerge from the partnership between the Swiss pharma giant and the Salt Lake City-based biotech. Recursion uses machine learning to analyze vast biological datasets, identifying potential drug targets and candidate molecules. Roche, one of the world's largest drugmakers, has been exploring AI to accelerate its R&D pipeline.
Neither company disclosed specific details about the disease area or the stage of the project. But the move signals that the collaboration, announced in 2021, is producing tangible results. At the time, Roche committed up to $1.5 billion in milestones and equity investment, though it is not clear how much of that has been triggered by this advancement.
Why AI matters in pharma
Traditional drug discovery can take more than a decade and cost billions. AI tools aim to shorten that timeline by predicting which molecules are most likely to succeed. Recursion's platform, for example, screens thousands of compounds in silico before moving to lab tests. For Roche, the project is a test case for whether AI can deliver on its promise in a large pharma setting.
The field has seen a surge of partnerships between tech-driven biotechs and established drugmakers. But many AI-discovered drugs have yet to reach the market. Roche's advancement of this project suggests confidence in the approach, though the path to a marketed medicine remains long.
What comes next for the program is unclear. Roche and Recursion have not announced a timeline for clinical trials or further milestones. The project's progress will be watched closely by an industry eager to see if AI can live up to the hype.
